Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Prevention |
RCV000254342 | SCV000302991 | benign | not specified | criteria provided, single submitter | clinical testing | ||
Labcorp Genetics |
RCV000969598 | SCV001117124 | benign | not provided | 2023-12-02 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000969598 | SCV001865396 | benign | not provided | 2020-07-30 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002365256 | SCV002658851 | likely benign | Inborn genetic diseases | 2022-03-07 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Clinical Genomics, |
RCV003445811 | SCV004174206 | uncertain significance | Maturity-onset diabetes of the young type 10 | criteria provided, single submitter | research | Potent mutations in the INS gene can cause early onset diabetes mellitus which is insulin dependent. May have poor response to sulfonylureas, mutations in this gene can cause beta cell destruction.However, more evidence is required to confer the association of this particular synonymous variant P21P/ rs11564720 with Maturity-onset diabetes of the young (MODY). | |
Breakthrough Genomics, |
RCV000969598 | SCV005321277 | benign | not provided | criteria provided, single submitter | not provided |